N@N

Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012

^{Published on 2012-11-27 13:15:42 - Market Wire}
 

Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012 -- RICHMOND, Calif., Nov. 27, 2012 /PRNewswire/ --

RICHMOND, Calif., Nov. 27, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: [ SGMO ]), announced today that it will host a live webcast of its upcoming Analyst and Investor Briefing which will be held in New York City at 5:00 pm ET on Thursday, December 6, 2012.  During the briefing, members of Sangamo's management team will provide an update on the company's technology platform advancements and pipeline of ZFP Therapeutics^® as well as near- and mid-term operating goals.

The presentations may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section [ http://investor.sangamo.com/index.cfm ] under Events and Presentations. A replay of the presentations will be archived on the Sangamo website and will be available approximately two hours after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and hemoglobinopathies such as sickle cell anemia and beta-thalassemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at [ www.sangamo.com ].

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

SOURCE Sangamo BioSciences, Inc.